Available Technologies
# of Displayed Technologies: 10 / 17
Applied Category Filter (Click To Remove): Other
Targeting Telomerase to Treat Ocular Neovascular Disorders
TS-065809 — Therapeutic strategies for treating ocular neovascular disorders by targeting telomerase.
Choroidal neovascularization (CNV) is the principal driver of blindness in neovascular age-related macular degeneration (nvAMD). Abnormal blood vessel growth beneath the macular leads to retinal damage and severe vision loss. Discovering the involvement of VEGF in the underlying mechanisms driving …
- College: College of Medicine (COM)
- Inventors: Kerur, Nagaraj
- Licensing Officer: Willson, Christopher
Enhancing Antibody Therapies Using a NOD2 Agonist
TS-065320 — Stimulating monocytes with a NOD2 agonist increases effectiveness of monoclonal antibody therapy.
An estimated 20,160 new cases of chronic lymphocytic leukemia (CLL) and 4,410 deaths were expected in 2022. Current therapies for CLL include the administration of a monoclonal antibody, such as rituximab, an anti-CD20 antibody, to promote clearance of malignant B cells.
The Need
Current therapies…
- College: College of Medicine (COM)
- Inventors: Tridandapani, Susheela; Butchar, Jonathan; Mehta, Payal; Merchand Reyes, Giovanna; Santhanam, Ramasamy
- Licensing Officer: Willson, Christopher
CDP-choline a host-directed therapeutic for disease caused by SARS CoV-2 infection.
TS-064192 — The Need: The global impact of the SARS CoV-2 coronavirus has created an urgent need for innovative medical interventions to address the challenges posed by COVID-19. Despite the availability of vaccines, sub-optimal vaccine uptake and concerns about new virus variants necessitate additional medical…
- College: College of Veterinary Medicine
- Inventors: Davis, Ian; Schelhorn, Jean
- Licensing Officer: Willson, Christopher
Transducin β-like protein 1 X-Linked Selective Degraders as Anti-cancer Therapeutics
TS-062685 — Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. The most common cancers are breast, lung, colon and rectum and prostate cancers.
The Need
Current cancer treatments mainly rely on chemotherapy, radiation, surgery and bon…
- College: College of Pharmacy
- Inventors: Cheng, Xiaolin; Alinari, Lapo; Li, Pui-Kai "Tom"; Yang, Rui
- Licensing Officer: Willson, Christopher
Underwater Zooplankton Enhancing Light Array (UZELA); A Novel Device for Stimulating Nutritional Therapy in Corals
TS-062571 —
The Need
Coral reefs are declining at an alarming rate. When temperatures increase by as little as 1-2 °C above their normal thermal maximum for as little as ten days, corals become stressed, lose their endosymbiotic algae, and turn white – hence the term bleaching. When bleached, corals…
- College: College of Arts & Sciences
- Inventors: Grottoli, Andrea; Dixon, Shannon; Hulver, Ann Marie; Jackson, Eric; Shea, Ryan; Steck, James
- Licensing Officer: Dahlman, Jason "Jay"
Modulation of Mismatch Repair and Genomic Stability by miR-155
TS-062322 — The Need
The field of molecular biology faces a critical commercial need in the effective diagnosis, treatment, and prevention of cancer-related disorders associated with mismatch repair (MMR) dysfunction. Diseases such as Lynch Syndrome (LS) and hereditary non-polyposis colorectal cancer (HNPCC), …
- College: College of Medicine (COM)
- Inventors: Croce, Carlo; Valeri, Nicola
- Licensing Officer: Willson, Christopher
Diagnosis of Chemoresistant Ovarian Cancer.
TS-062306 — The Need
Ovarian cancer is a significant health concern, being the leading cause of gynecological cancer-related deaths in the developed world. Current treatments, such as platinum-based chemotherapy, have limited success due to issues like late-stage diagnosis and chemoresistance. Identifying mole…
- College: College of Medicine (COM)
- Inventors: Croce, Carlo; Vecchione, Andrea
- Licensing Officer: Willson, Christopher
Microrna-21, Mismatch Repair, and Colorectal Cancer
TS-062305 — The Need: Colorectal cancer (CRC) is a significant health concern, with a high incidence rate and limited treatment options, particularly regarding resistance to standard chemotherapy like 5-fluorouracil (5-FU). The management of CRC patients is complicated by the frequent occurrence of primary or a…
- College: College of Medicine (COM)
- Inventors: Croce, Carlo; Valeri, Nicola
- Licensing Officer: Willson, Christopher
Advancing Cancer-Related Technology for Better Prognosis and Treatment
TS-062303 — The Need:
Cancer continues to be a significant global health challenge, with conditions like non-small cell lung cancer (NSCLC) and hepatocellular carcinoma (HCC) often diagnosed at advanced stages, resulting in poor prognoses. Existing treatment methods, such as TRAIL-based therapy, face obstacle…
- College: College of Medicine (COM)
- Inventors: Croce, Carlo
- Licensing Officer: Willson, Christopher
MicroRNA signatures in human ovarian cancer
TS-062298 — The Need:
Ovarian cancer remains a significant challenge in the field of medicine, with late-stage diagnosis and limited effective treatments contributing to high mortality rates. The need for improved diagnostic tools and targeted therapies is evident to address this aggressive disease. Convention…
- College: College of Medicine (COM)
- Inventors: Croce, Carlo
- Licensing Officer: Willson, Christopher
